Geron (NASDAQ:GERN) Stock Price Down 8.5% – Should You Sell?

Geron Co. (NASDAQ:GERNGet Free Report) fell 8.5% on Monday . The company traded as low as $2.85 and last traded at $2.90. 3,819,957 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 11,759,547 shares. The stock had previously closed at $3.17.

Analyst Upgrades and Downgrades

GERN has been the topic of a number of research reports. Needham & Company LLC raised their target price on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Scotiabank initiated coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Read Our Latest Stock Report on GERN

Geron Stock Performance

The stock has a 50 day moving average of $3.76 and a two-hundred day moving average of $4.20. The stock has a market capitalization of $1.78 billion, a PE ratio of -9.19 and a beta of 0.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Geron (NASDAQ:GERNGet Free Report) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. The company had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business’s revenue was up 17138.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.08) EPS. Research analysts expect that Geron Co. will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP purchased a new position in Geron in the 3rd quarter valued at approximately $200,268,000. Darwin Global Management Ltd. acquired a new stake in Geron in the second quarter valued at $106,185,000. Holocene Advisors LP purchased a new position in shares of Geron in the third quarter valued at $82,498,000. Janus Henderson Group PLC increased its position in shares of Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after buying an additional 13,163,889 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its position in shares of Geron by 124.6% in the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after buying an additional 9,342,000 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Featured Stories

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.